

#### STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005 VERMONT

#### LIST OF TABLES

#### OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

#### FOR ALL MEDICAID BENEFICIARIES

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

#### FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY

BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,

BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES

AMONG NONDUALS

#### FOR DUAL ELIGIBLE BENEFICIARIES

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS. BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS. BY BENEFICIARY CHARACTERISTIC

TABLE D.12, USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

#### SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL

ELIGIBLE BENEFICIARIES

TABLE D.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY<sup>a, b</sup>
DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

		١	Number of E			ES, VERMON	,	Nur	mber of Be	nefit Mor	nths	
Beneficiary						Other/						Other/
Characteristics	All	Aged	Disabled		Children	Unknown	All	Aged	Disabled	Adults	Children	Unknown
All	31,392	18,577	12,202	604	8	1	329,992	191,607	132,476	5,833	73	3
Age												
5 and younger	1	0	1	0	0	0	12	0	12	0	0	0
6-14	1	0	1	0	0	0	12	0	12	0	0	0
15-20	50	0	42	2	6	0	551	0	474	21	56	0
21-44	4,408	0	4,124	283	1	0	47,340	0	44,566	2,769	5	0
45-64	6,874	3	6,636	234	1	0	73,850	29	71,606	2,203	12	0
65-74	7,341	6,190	1,069	81	0	1	77,203	64,239	12,163	798	0	3
75-84	7,887	7,604	280	3	0	0	82,725	79,582	3,113	30	0	0
85 and older	4,830	4,780	49	1	0	0	48,299	47,757	530	12	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	19,291	12,944	6,042	299	5	1	205,259	135,994	66,227	2,989	46	3
Male	12,101	5,633	6,160	305	3	0	124,733	55,613	66,249	2,844	27	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	21,119	10,468	10,182	464	5	0	226,649	110,444	111,525	4,628	52	0
African American	93	12	76	5	0	0	949	123	775	51	0	0
Other/unknown	10,180	8,097	1,944	135	3	1	102,394	81,040	20,176	1,154	21	3
Use of Nursing Facilities <sup>c</sup>												
Entire year	2,265	2,147	118	0	0	0	21,475	20,261	1,214	0	0	0
Part year	1,055	891	161	3	0	0	10,388	8,695	1,662	31	0	0
None	28,072	15,539	11,923	601	8	1	298,129	162,651	129,600	5,802	73	3
Maintenance Assistance Statu	ıs											
Cash	7,063	1,402	5,606	54	1	0	80,296	15,574	64,127	583	12	0
Medically needy	6,571	3,366	3,110	92	3	0	69,597	36,003	32,689	883	22	0
Poverty-related	14	0	0	13	0	1	106	0	0	103	0	3
Other/unknown	17,744	13,809	3,486	445	4	0	179,993	140,030	35,660	4,264	39	0
Dual Medicare Status <sup>d</sup>												
Full dual, all year	31,392	18,577	12,202	604	8	1	329,992	191,607	132,476	5,833	73	3
Full dual, part year	0	0	0	0	0	0	0	0	0	0	0	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	31,392	18,577	12,202	604	8	1	329,992	191,607	132,476	5,833	73	3
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

a. Table D.2 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2005. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE D.3 ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of	Mean Rx \$	¢ nor Dv	Mean \$, All Medicaid FFS \$c	Rx \$ as a Percentage of All Medicaid FFS \$d	Number of Beneficiaries
All	92.4		\$3,265	\$ per KX	\$11,439	28.5	31,392
Age	<b>V</b>		40,200	•••	<b>V</b> 11,100	20.0	0.,002
5 and younger	100.0	79.0	15,889	201	48,177	33.0	1
6-14	100.0	150.0	14,870	99	16,644	89.3	1
15-20	80.0	21.1	2,083	99	17,763	11.7	50
21-44	88.9	38.1	3,675	97	14,308	25.7	4,408
45-64	92.9	56.1	4,512	80	12,437	36.3	6,874
65-74	91.5	46.8	2,940	63	7,374	39.9	7,341
75-84	93.3	49.3	2,804	57	10,027	28.0	7,887
85 and older	94.9	49.0	2,368	48	15,813	15.0	4,830
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibility	/e						
Aged	93.1	47.6	2,688	56	10,380	25.9	18,577
Disabled	91.6	50.6	4,150	82	13,232	31.4	12,202
Adults	87.4	36.7	3,108	85	7,820	39.7	604
Children	100.0	28.6	2,657	93	12,755	20.8	8
Unknown	100.0	3.0	705	235	792	89.0	1
Gender							
Female	94.9	52.4	3,287	63	11,471	28.7	19,291
Male	88.4	42.5	3,229	76	11,389	28.4	12,101
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	92.8	52.4	3,549	68	12,997	27.3	21,119
African American	84.9	37.2	3,670	99	7,980	46.0	93
Other/unknown	91.7	40.8	2,670	65	8,239	32.4	10,180
Use of Nursing Fa	acilities <sup>f</sup>						
Entire year	97.0	68.1	3,552	52	41,479	8.6	2,265
Part year	96.6	70.6	3,765	53	28,345	13.3	1,055
None	91.9	46.2	3,223	70	8,380	38.5	28,072
Maintenance Assi	istance Status						
Cash	90.8	50.4	3,623	72	13,839	26.2	7,063
Medically needy	90.3	49.0	3,542	72	6,979	50.7	6,571
Poverty related	92.9	13.4	736	55	4,608	16.0	14
Other/unknown	93.8	47.7	3,021	63	12,141	24.9	17,744

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.3 includes beneficiaries represented by Cell G of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

TABLE D.4 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC $^{a,\,b}$  DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

			-		Nun	nber of Rx, P	ercentage v	vith:			Numbe	er
Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>c</sup>	None		More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10	Mean \$, All Medicaid FFS \$ <sup>d</sup>	Beneficiaries	Benefit Months
All	4.6	\$311	28.5	7.6	15.1	12.4	33.2	24.8	6.9	\$1,088	31,392	329,992
Age												
5 and younger	6.6	1,324	33.0	0.0	0.0	0.0	0.0	100.0	0.0	4,015	1	12
6-14	12.5	1,239	89.3	0.0	0.0	0.0	0.0	0.0	100.0	1,387	1	12
15-20	1.9	189	11.7	20.0	40.0	16.0	12.0	10.0	2.0	1,612	50	551
21-44	3.5	342	25.7	11.1	25.4	15.0	28.5	15.5	4.5	1,332	4,408	47,340
45-64	5.2	420	36.3	7.1	14.8	10.0	31.1	27.8	9.1	1,158	6,874	73,850
65-74	4.4	280	39.9	8.5	15.1	13.4	32.5	24.2	6.3	701	7,341	77,203
75-84	4.7	267	28.0	6.7	12.2	12.7	35.6	26.3	6.6	956	7,887	82,725
85 and older	4.9	237	15.0	5.1	11.0	11.2	37.7	27.9	7.2	1,581	4,830	48,299
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility	<sub>/</sub> e											
Aged	4.6	261	25.9	6.9	13.0	12.7	35.3	25.7	6.4	1,006	18,577	191,607
Disabled	4.7	382	31.4	8.4	18.0	12.0	30.1	23.8	7.8	1,219	12,202	132,476
Adults	3.8	322	39.7	12.6	22.5	11.8	29.5	21.4	2.3	810	604	5,833
Children	3.1	291	20.8	0.0	25.0	25.0	25.0	25.0	0.0	1,398	8	73
Unknown	1.0	235	89.0	0.0	100.0	0.0	0.0	0.0	0.0	264	1	3
Gender												
Female	4.9	309	28.7	5.1	13.1	12.4	35.0	26.8	7.5	1,078	19,291	205,259
Male	4.1	313	28.4	11.6	18.4	12.3	30.3	21.7	5.8	1,105	12,101	124,733
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	4.9	331	27.3	7.2	14.7	11.4	32.0	26.5	8.1	1,211	21,119	226,649
African American	3.6	360	46.0	15.1	28.0	8.6	28.0	17.2	3.2	782	93	949
Other/unknown	4.1	266	32.4	8.3	15.8	14.3	35.7	21.5	4.4	819	10,180	102,394
Use of Nursing Fa	cilities <sup>f</sup>											
Entire year	7.2	375	8.6	3.0	5.0	5.6	25.3	39.4	21.7	4,375	2,265	21,475
Part year	7.2	382	13.3	3.4	6.4	5.7	29.6	37.7	17.2	2,879	1,055	10,388
None	4.3	303	38.5	8.1	16.3	13.2	34.0	23.2	5.3	789	28,072	298,129
Maintenance Assi	stance Status	3										
Cash	4.4	319	26.2	9.2	19.1	12.4	29.7	22.2	7.2	1,217	7,063	80,296
Medically needy	4.6	334	50.7	9.7	16.0	11.5	30.8	25.2	6.7	659	6,571	69,597
Poverty related	1.8	97	16.0	7.1	50.0	21.4	14.3	7.1	0.0	609	14	106
Other/unknown	4.7	298	24.9	6.2	13.2	12.7	35.5	25.8	6.7	1,197	17,744	179,993

a. Table D.4 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.5 AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

		All Rx		Patente	d Brand Drugs	I-Name	Off-Pater	nt Bran Drugs	d-Name	Gen	eric Dı	าเตร
Beneficiary	Number	7111100		Number	Diago		Number	Drago		Number	0110 21	ugo
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	4.6	\$311	\$67	1.8	\$234	\$131	0.2	\$16	\$94	2.7	\$61	\$23
Age												
5 and younger	6.6	1,324	201	4.6	1,302	284	0.1	1	16	1.9	20	11
6-14	12.5	1,239	99	7.6	1,142	151	0.3	5	19	4.7	93	20
15-20	1.9	189	99	1.0	161	159	0.0	1	42	0.9	27	30
21-44	3.5	342	97	1.4	254	181	0.2	26	168	2.0	62	31
45-64	5.2	420	80	2.0	310	153	0.2	27	133	3.0	83	28
65-74	4.4	280	63	1.8	216	122	0.1	11	74	2.5	53	21
75-84	4.7	267	57	1.8	206	114	0.2	9	54	2.7	52	19
85 and older	4.9	237	48	1.8	176	101	0.2	9	48	3.0	52	17
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility	d											
Aged	4.6	261	56	1.8	200	113	0.2	9	58	2.7	52	19
Disabled	4.7	382	82	1.8	285	156	0.2	25	133	2.6	72	27
Adults	3.8	322	85	1.3	210	161	0.1	30	210	2.4	81	35
Children	3.1	291	93	1.9	266	140	0.0	0	0	1.2	25	20
Unknown	1.0	235	235	1.0	235	235	0.0	0	0	0.0	0	0
Gender												
Female	4.9	309	63	1.9	233	123	0.2	15	81	2.8	61	22
Male	4.1	313	76	1.6	236	147	0.1	17	123	2.4	60	25
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Race												
White	4.9	331	68	1.9	248	133	0.2	17	97	2.8	65	23
African American	3.6	360	99	1.5	285	189	0.1	21	186	2.0	54	27
Other/unknown	4.1	266	65	1.6	204	128	0.1	12	84	2.3	50	22
Use of Nursing Fa	cilities <sup>e</sup>											
Entire year	7.2	375	52	2.6	277	108	0.3	15	55	4.3	83	19
Part year	7.2	382	53	2.6	286	108	0.2	15	62	4.3	82	19
None	4.3	303	70	1.7	229	135	0.2	16	100	2.5	58	23
Maintenance Assi	stance Sta	tus										
Cash	4.4	319	72	1.7	242	140	0.2	18	108	2.5	58	23
Medically needy	4.6	334	72	1.8	249	139	0.2	20	109	2.7	66	25
Poverty related	1.8	97	55	0.4	65	151	0.0	0	47	1.3	31	24
Other/unknown	4.7	298	63	1.8	225	125	0.2	13	80	2.7	60	22

a. Table D.5 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9ad778d7b6615 (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or hidness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

## TABLE D.6 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

		nber of R Ionth Am			\$ per	Benefit N		nong		\$ per	·Rx			-		Userse	
Therapeutic Category	P Total	atented Brand- Name	Brand-	Generic		atented Brand- Name	Off- Patent Brand- Name 0	Seneric	P Total	atented Brand- Name	Off- Patent Brand- Name (	Generic	Total Number of Rx	Total Rx \$		As a Percentage of Dual Benes	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$22	\$14	\$3	\$4	\$65	\$206	\$82	\$19	58,653	\$3,784,970	15,899	50.6	174,415
Biologicals	0.1	0.1	0.0	0.1	93	5	31	57	681	80	3,409	817	341	232,084	226	0.7	2,504
Antineoplastic Agents	0.7	0.2	0.0	0.5	124	103	1	21	183	507	185	44	6,236	1,139,196	874	2.8	9,163
Endocrine/Metabolic Drugs	1.0	0.4	0.1	0.6	53	38	5	10	51	107	42	18	157,191	8,056,800	14,106	44.9	152,990
Cardiovascular Agents	1.9	0.7	0.0	1.2	86	67	1	18	46	101	33	16	431,329	19,863,368	21,349	68.0	230,296
Respiratory Agents	8.0	0.5	0.0	0.2	63	57	2	4	82	112	70	18	88,259	7,280,104	10,492	33.4	114,840
Gastrointestinal Agents	0.8	0.5	0.0	0.3	75	69	1	6	91	141	92	17	110,986	10,130,619	12,441	39.6	135,162
Genitourinary Agents	0.6	0.5	0.0	0.1	42	38	1	3	71	85	74	23	29,443	2,080,181	4,556	14.5	49,790
CNS Drugs	1.4	0.6	0.0	0.8	126	102	4	20	87	162	185	25	259,280	22,647,496	16,716	53.2	179,685
Stimulants/Anti-obesity/Anorexia	0.7	0.4	0.0	0.3	85	69	4	12	122	189	130	39	5,086	617,988	668	2.1	7,309
Miscellaneous Psychological/ Neurological Agents Analgesics and Anesthetics	0.7 0.9	0.7 0.2	0.0	0.0 0.7	120 57	117 23	0 11	3 23	171 65	177 150	60 263	69 34	15,541 139,591	2,658,711 9,105,483	2,074 14.601	6.6 46.5	22,169 158,587
Neuromuscular Agents	1.0	0.3	0.1	0.7	82	49	5	28	82	165	95	43	93,529	7,650,225	8.573		93,640
Nutritional Products	0.6	0.0	0.0	0.6	11	0	0	10	18	25	25	17	23,278	412,578	3.669		39,205
Hematological Agents	0.8	0.3	0.0	0.5	63	52	2	9	75	203	41	17	51.664	3.875.430	5.812		61,980
Topical Products	0.4	0.2	0.0	0.2	20	14	1	5	51	88	53	23	49,850	2,520,818	11.431	36.4	126,266
Miscellaneous Products	0.2	0.1	0.0	0.1	35	23	4	8	149	168	464	90	2,514	375,595	973		10,618
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	8	0	0	0	28	0	0	0	1,673	46.385	534		5,878
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	1,524,444	102,478,031	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.6 includes the beneficiaries represented by Cell G of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Vermont, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

TABLE D.7 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

	<u>-</u>		Users		Am	nong Use	rs
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of Dual Beneficiaries	Number of Benefit Months		\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$13,540,751	7,027	22.4	76,610	0.9	\$195	\$177
ANTIHYPERLIPIDEMIC	10,904,083	12,166	38.8	135,787	0.7	118	80
ULCER DRUGS	8,901,536	11,940	38.0	131,434	0.7	96	68
ANTIDEPRESSANTS	7,369,367	15,753	50.2	172,233	0.7	58	43
ANTICONVULSANT	6,528,032	7,216	23.0	79,599	0.9	95	82
ANTIASTHMATIC	5,921,282	12,110	38.6	133,082	0.5	92	44
ANALGESICS - Narcotic	5,081,422	15,686	50.0	172,195	0.5	59	30
ANTIDIABETIC	5,017,611	9,237	29.4	100,973	0.8	65	50
ANTIHYPERTENSIVE	3,332,596	12,634	40.2	138,775	0.7	34	24
ANALGESICS - ANTI-INFLAMMATORY	3,062,729	7,470	23.8	83,565	0.4	82	37
Total	69,659,409	111,239		1,224,253	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table D.7 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

b. Medicaid relinious entent amounts presented in this table do not relied receitally equired residates from roug manufacturers to the state.

C. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx/2contentId=0980f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$

<sup>=</sup> Medicaid reimbursement; n.a. = not applicable.

# TABLE D.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

All Top 10 Drug Groups ANTIPSYCHOTICS ANTIHYPERLIPIDEMIC

Beneficiary Characteristics	Number of Rx	Rx\$	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx per F Benefit	Mean Rx \$ per Benefit Month
All	812,057	\$69,659,409	7,027	22.4	76,610	0.9	\$177	12,166	38.8	135,787	0.7	\$80
Female												
All Females	517,780	42,091,365	3,998	20.7	43,581	0.9	149	7,539	39.1	84,737	0.7	81
Female, Disabled												
All Ages	208,250	19,085,942	2,185	36.2	24,662	1.0	182	2,046	33.9	23,309	0.7	76
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	43	2,379	0	0.0	0	0.0	0	1	100.0	12	0.8	27
15-20	324	27,157	4	30.8	48	2.1	323	0	0.0	0	0.0	0
21-44	51,291	5,109,027	828	45.0	9,287	0.8	170	252	13.7	2,884	0.6	64
45-64	124,800	11,385,280	1,178	36.2	13,321	1.0	194	1,260	38.8	14,228	0.7	75
65-74	25,126	2,053,348	136	19.6	1,578	0.9	168	418	60.1	4,858	0.7	82
75-84	5,945	461,210	35	17.2	388	0.7	127	100	49.3	1,151	0.8	83
85 and older	721	47,541	4	10.5	40	0.3	19	15	39.5	176	0.8	89
Female, Other Eligibles												
All Ages	309,530	23,005,423	1,813	13.7	18,919	0.7	106	5,493	41.5	61,428	0.7	84
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	48	4,145	0	0.0	0	0.0	0	0	0.0	0	0.0	0
21-44	3,632	300,796	46	31.9	453	0.6	117	12	8.3	114	0.5	59
45-64	3,513	337,779	35	31.3	395	0.6	143	35	31.3	380	0.6	75
65-74	96,111	7,834,050	413	10.5	4,463	0.8	122	2,128	54.3	23,641	0.7	83
75-84	126,939	9,413,689	604	11.4	6,415	0.7	107	2,468	46.7	27,886	0.7	85
85 and older	79,287	5,114,964	715	18.9	7,193	0.7	91	850	22.5	9,407	0.7	83
Male												
All Males	294,277	27,568,044	3,029	25.0	33,029	1.0	214	4,627	38.2	51,050	0.7	79
Male, Disabled												
All Ages	170,241	18,017,975	2,299	37.3	25,860	1.0	242	1,995	32.4	22,538	0.7	75
5 and younger	10	1,037	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	178	17,247	4	13.8	48	0.6	59	0	0.0	0	0.0	0
21-44	51,172	6,173,240	1,085	47.5	12,196	1.0	237	344	15.1	3,878	0.6	65
45-64	106,108	10,712,423	1,129	33.3	12,689	1.1	250	1,445	42.7	16,302	0.7	76
65-74	10,675	950,473	67	17.9	780	1.1	233	179	47.9	2,073	0.7	83
75-84	1,943	153,893	14	18.2	147	0.8	154	23	29.9	237	0.7	76
85 and older	155	9,662	0	0.0	0	0.0	0	4	36.4	48	0.6	70

# TABLE D.7A MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

All Top 10 Drug Groups **ANTIPSYCHOTICS ANTIHYPERLIPIDEMIC** Mean Mean Number of Number Number of Number Users Benefit Mean Users Benefit of Rx Mean of Rx per Rx \$ per as % Months per Rx \$ per as % Months of Dual Benefit Benefit Number of Among Benefit Benefit Beneficiary Number of Among of Dual Characteristics Number of Rx Rx\$ Users Benes Users Month Month Users Benes Users Month Month Male, Other Eligibles All Ages 124,036 9,550,069 730 12.3 7,169 0.8 109 2,632 44.3 28,512 0.7 81 0.0 5 and younger 0 0 0 0.0 0 0 0 0.0 0 0.0 0 0 0 6-14 0 0 0 0.0 0 0.0 0 0.0 0 0.0 12 457 0 0 0 0 0 15-20 0.0 0 0.0 0.0 0.0 3,326 32 22.9 349 120 421 69 21-44 364,597 0.5 37 26.4 0.5 45-64 2,844 233,116 13 10.3 137 119 58 46.0 630 0.7 71 0.6 65-74 54.074 4,206,134 189 8.0 1.997 0.8 131 1.298 55.2 14.019 0.7 81 75-84 47,308 3,609,580 314 13.6 3,097 8.0 105 44.0 11,136 0.7 83 1,020 85 and older 16,472 1,136,185 182 18.1 1,589 0.7 87 219 21.8 2,306 0.7 84 Unknown 0 0.0 0 0.0 0 0 0.0 0 0.0 0

a. Table D.7A includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

### TABLE D.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

		ULC	ER DRUGS	;			ANTI	DEPRESSAN	TS			ANTI	CONVULSAN	NT	
Beneficiary Characteristics	Number of Users	Users as % of Dual	Number of Benefit N Months Among Users	Mean Number of Rx per f Benefit Month		Number of Users	Users as % of Dual Benes	Number of Benefit N Months Among Users	Mean Number of Rx per Benefit Month		Number of Users	Users as % of Dual Benes	Number of Benefit N Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	11,940	38.0	131,434	0.7	\$68	15,753	50.2	172,233	0.7	\$43	7,216	23.0	79,599	0.9	\$82
Female															
All Females	7,999	41.5	88,610	0.7	68	10,717	55.6	117,765	0.7	43	4,380	22.7	48,395	0.8	77
Female, Disabled															
All Ages	2,733	45.2	31,065	0.7	69	5,027	83.2	56,437	0.7	47	2,550	42.2	28,617	0.9	98
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
6-14	1	100.0	12	1.0	103	0	0.0	0	0.0	0	1	100.0	12	0.3	9
15-20	3	23.1	35	0.6	40	8	61.5	89	1.2	59	6	46.2	72	1.0	64
21-44	616	33.4	6,973	0.6	57	1,589	86.3	17,925	0.7	47	919	49.9	10,358	0.9	103
45-64	1,613	49.6	18,247	0.7	73	2,954	90.9	32,918	0.8	49	1,443	44.4	16,064	0.9	97
65-74	375	54.0	4,350	0.7	69	385	55.4	4,453	0.7	37	136	19.6	1,582	0.9	85
75-84	106	52.2	1,236	0.8	69	80	39.4	926	0.8	41	40	19.7	469	0.7	53
85 and older	19	50.0	212	0.7	65	11	28.9	126	0.8	34	5	13.2	60	0.9	70
Female, Other Eligibles															
All Ages	5,266	39.7	57,545	0.7	67	5,690	42.9	61,328	0.8	40	1,830	13.8	19,778	0.8	47
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
15-20	0	0.0	0	0.0	0	2	50.0	24	0.2	22	1	25.0	12	0.7	10
21-44	45	31.3	467	0.5	54	160	111.1	1,706	0.6	45	65	45.1	701	0.7	88
45-64	46	41.1	502	0.6	73	129	115.2	1,405	0.7	53	48	42.9	496	0.7	76
65-74	1,522	38.8	16,775	0.7	73	1,588	40.5	17,407	0.7	40	566	14.4	6,122	0.8	54
75-84	2,129	40.2	23,627	0.7	65	2,192	41.4	23,808	0.7	38	721	13.6	7,885	0.7	4
85 and older	1,524	40.3	16,174	0.8	65	1,619	42.9	16,978	0.9	40	429	11.4	4,562	0.8	39
Male															
All Males	3,941	32.6	42,824	0.7	68	5,036	41.6	54,468	0.7	42	2,836	23.4	31,204	0.9	90
Male, Disabled															
All Ages	1,972	32.0	22,095	0.7	66	3,259	52.9	36,267	0.7	44	2,069	33.6	23,200	0.9	101
5 and younger	1	100.0	12	0.3	25	0	0.0	0	0.0	0	1	100.0	12	0.6	62
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	(
15-20	3	10.3	36	0.4	117	8	27.6	87	0.5	22	7	24.1	84	0.6	90
21-44	539	23.6	6,023	0.6	55	1,195	52.4	13,310	0.7	42	809	35.5	9,169	0.9	114
45-64	1,235	36.5	13,788	0.8	69	1,918	56.6	21,293	0.7	46	1,161	34.3	12,924	0.9	94
65-74	159	42.5	1,842	0.7	71	113	30.2	1,293	0.8	43	81	21.7	907	0.8	82
75-84	33	42.9	370	0.8	92	23	29.9	260	0.7	37	9	11.7	92	0.8	42
85 and older	2	18.2	24	1.0	117	2	18.2	24	1.0	52	1	9.1	12	0.9	47

### TABLE D.7B MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>
DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

	-	ULC	ER DRUGS		LLIOIDLL	BENEI ICIAN		EPRESSAN	TS			ANT	ICONVULSAN	1T	
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean
		as %	Months	Rx per l	Rx \$ per		as %	Months	Rx per l	Rx \$ per		as %	Months	Rx per F	₹x \$ per
Description Observations	Number of	of Dual	Among			Number of	of Dual	Among				of Dual	Among	Benefit	
Beneficiary Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Eligibles															
All Ages	1,969	33.1	20,729	0.7	70	1,777	29.9	18,201	0.7	38	767	12.9	8,004	0.8	58
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	1	25.0	5	0.2	44	0	0.0	0	0.0	0	0	0.0	0	0.0	0
21-44	47	33.6	512	0.5	59	97	69.3	1,057	0.5	37	60	42.9	671	0.6	66
45-64	31	24.6	328	0.6	63	68	54.0	728	0.6	40	31	24.6	313	0.8	72
65-74	747	31.8	8,012	0.7	73	635	27.0	6,778	0.7	38	306	13.0	3,286	0.9	62
75-84	804	34.7	8,530	0.7	69	638	27.5	6,572	0.7	37	267	11.5	2,791	0.8	52
85 and older	339	33.8	3,342	0.7	69	339	33.8	3,066	8.0	41	103	10.3	943	0.9	46
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.7B includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

## TABLE D.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005 ANALGESICS - Narcotic

ANTIDIADETIC ANTIACTUMATIC

		ANT	TIASTHMATIC	;			ANALG	ESICS - Nard	cotic			AN	TIDIABETIC		
Beneficiary Characteristics	Number of Users	Users as % of Dual Benes	Number of Benefit N Months Among Users	Mean lumber of Rx per I Benefit Month		Number of Users	Users as % of Dual Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month	Number of Users	Users as % of Dual Benes	Number of Benefit N Months Among Users		Mean Rx \$ per Benefit Month
All	12,110	38.6	133,082	0.5	\$45	15,686	50.0	172,195	0.5	\$30	9,237	29.4	100,973	0.8	\$50
Female															
All Females	7,679	39.8	84,905	0.5	43	10,147	52.6	112,166	0.5	25	5,688	29.5	62,717	0.8	49
Female, Disabled	i														
All Ages	3,076	50.9	34,733	0.4	36	4,446	73.6	50,247	0.5	33	1,747	28.9	19,708	0.8	55
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
6-14	3	300.0	36	0.4	19	2	200.0	24	0.1	1	0	0.0	0	0.0	C
15-20	3	23.1	36	0.1	2	7	53.8	84	0.1	1	2	15.4	24	0.1	5
21-44	738	40.1	8,336	0.3	24	1,472	79.9	16,572	0.5	32	246	13.4	2,794	0.7	57
45-64	1,792	55.1	20,105	0.4	38	2,439	75.0	27,465	0.6	37	1,083	33.3	12,135	0.8	56
65-74	440	63.3	5,082	0.5	45	410	59.0	4,751	0.4	20	336	48.3	3,875	0.8	54
75-84	92	45.3	1,050	0.5	49	104	51.2	1,221	0.4	14	73	36.0	806	0.8	44
85 and older	8	21.1	88	0.6	38	12	31.6	130	0.4	9	7	18.4	74	0.5	20
Female, Other El	igibles														
All Ages	4,603	34.7	50,172	0.5	48	5,701	43.0	61,919	0.4	19	3,941	29.7	43,009	0.8	46
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
15-20	2	50.0	10	0.3	26	4	100.0	34	1.0	96	0	0.0	0	0.0	C
21-44	56	38.9	640	0.3	21	158	109.7	1,706	0.6	26	17	11.8	193	0.6	54
45-64	57	50.9	654	0.4	36	108	96.4	1,202	0.6	29	25	22.3	282	0.6	65
65-74	1,582	40.3	17,237	0.5	52	1,656	42.2	18,177	0.4	17	1,460	37.2	16,047	0.8	54
75-84	1,932	36.5	21,226	0.5	48	2,250	42.5	24,797	0.4	17	1,723	32.6	18,995	0.8	44
85 and older	974	25.8	10,405	0.5	42	1,525	40.4	16,003	0.5	21	716	19.0	7,492	0.8	35
Male															
All Males	4,431	36.6	48,177	0.5	48	5,539	45.8	60,029	0.5	38	3,549	29.3	38,256	0.7	51
Male, Disabled															
All Ages	2,034	33.0	22,805	0.5	43	3,411	55.4	37,653	0.6	46	1,525	24.8	16,831	0.7	58
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
15-20	5	17.2	60	0.2	8	11	37.9	128	0.1	1	0	0.0	0	0.0	C
21-44	431	18.9	4,897	0.3	25	1,208	52.9	13,426	0.5	41	274	12.0	3,035	0.7	59
45-64	1,354	40.0	15,108	0.5	47	1,997	59.0	21,936	0.6	51	1,066	31.5	11,693	0.8	58
65-74	188	50.3	2,105	0.6	55	171	45.7	1,889	0.5	28	153	40.9	1,777	0.7	55
75-84	55	71.4	623	0.6	46	18	23.4	202	0.4	7	30	39.0	302	0.8	68
85 and older	1	9.1	12	0.1	1	6	54.5	72	0.3	2	2	18.2	24	0.8	8

## TABLE D.7C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY BY SEX BASIS OF ELIGIBILITY AND AGE<sup>a, b, c</sup>

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>
DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

					DUAL	LIGIDLE DEN	IEFICIARII	ES, VERIVIONI	, 2005						
		ANT	TIASTHMATIC				ANALG	ESICS - Naro	cotic			1A	NTIDIABETIC		
			Number of	Mean				Number of	Mean				Number of	Mean	
		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean
		as %	Months	Rx per	Rx \$ per		as %	Months	Rx per	Rx \$ per		as %	Months	Rx per F	Rx \$ per
Beneficiary	Number of	of Dual	Among	Benefit	Benefit	Number of	of Dual	Among	Benefit	Benefit	Number of	of Dual	Among	Benefit	Benefit
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month
Male, Other Elig	ibles														
All Ages	2,397	40.3	25,372	0.5	52	2,128	35.8	22,376	0.4	25	2,024	34.1	21,425	0.7	45
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
21-44	32	22.9	364	0.3	24	137	97.9	1,479	0.8	96	10	7.1	110	0.9	72
45-64	27	21.4	292	0.3	25	94	74.6	982	0.6	44	43	34.1	455	0.8	53
65-74	1,013	43.1	10,930	0.6	53	844	35.9	8,944	0.4	20	1,016	43.2	10,958	0.7	50
75-84	986	42.6	10,472	0.5	53	749	32.3	8,004	0.4	18	747	32.2	7,883	0.7	42
85 and older	339	33.8	3,314	0.5	51	304	30.3	2,967	0.4	16	208	20.7	2,019	0.8	30
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.7C includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

### TABLE D.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

ANALGESICS - ANTI-INFLAMMATORY ANTIHYPERTENSIVE Number of Mean Number of Mean Users Users Benefit Number of Mean Benefit Number of Mean Rx per Rx \$ per as % Rx per Rx \$ per as % Months Months Benefit Benefit Number of Beneficiary Number of of Dual Among Benefit Number of of Dual Among Benefit Number of Characteristics Benes Users Month Beneficiaries Benefit Months Users Users Month Month Benes Users Month ΑII 12.634 40.2 138.775 0.7 \$24 7.470 23.8 83.565 0.4 \$37 31.392 329.992 Female All Females 8,044 41.7 88,980 0.7 26 4,967 25.7 55,835 0.5 38 19,291 205,259 Female, Disabled 2,084 All Ages 1,698 28.1 19,151 0.7 21 34.5 23,686 0.4 37 6,042 66,227 0.0 0 0 5 and younger 0 0.0 0 0 0.0 0 0.0 0 0 2 6-14 1 100.0 12 0.2 0 0.0 0 0.0 0 1 12 15-20 1 7.7 9 0.4 10 2 15.4 24 0.3 2 13 144 21-44 198 10.7 2,217 0.7 15 607 33.0 6,893 0.3 18 1,842 20,031 45-64 1,010 31.1 11,262 0.7 21 1,194 36.7 13,493 0.5 43 3,250 35,380 65-74 364 52.4 4,217 0.8 25 226 32.5 2,632 0.5 57 695 7,948 1,275 25 203 75-84 110 54.2 0.7 49 24.1 572 0.5 56 2,305 14 72 85 and older 14 36.8 159 0.7 6 15.8 0.2 10 38 407 Female, Other Eligibles All Ages 6,346 47.9 69,829 0.7 27 2,883 21.8 32,149 0.5 38 13,249 139,032 0 0.0 0.0 0 0.0 0 0.0 0 0 0 0 0 5 and younger 6-14 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 15-20 0 0.0 0 0.0 0 0 0.0 0 0.0 0 4 38 8.3 21-44 12 129 0.6 25 63 43.8 667 0.4 12 144 1,424 55 45-64 29 25.9 330 0.4 16 49.1 604 0.3 38 112 1,118 65-74 1,870 47.7 20,509 0.7 28 947 24.2 10,631 0.4 42 3.921 41,282 75-84 2,777 52.5 31,030 0.7 28 21.9 13,127 37 5,290 56,602 1,158 0.5 85 and older 1,658 43.9 17,831 0.8 26 660 17.5 7,120 0.6 37 3,778 38,568 Male All Males 4,590 37.9 49,795 0.7 21 2,503 20.7 27,730 0.4 34 124,733 12,101 Male, Disabled All Ages 1,723 28.0 20 1,506 16,874 35 6,160 66,249 19,164 0.7 24.4 0.4 0 0.0 0 0.0 0 0.0 0 0.0 0 5 and younger 0 1 12 6-14 0 0.0 0 0.0 0 0 0.0 0 0.0 0 0 0 15-20 1 3.4 12 1.0 8 2 6.9 24 0.1 1 29 330 21-44 319 14.0 3.539 0.6 17 497 21.8 5,570 0.3 33 2.282 24,535 45-64 1,173 34.6 12,983 0.7 20 897 26.5 10,010 0.5 37 3,386 36,226 65-74 183 48.9 2,088 0.7 20 86 23.0 986 0.5 27 374 4,215 77 75-84 41 53.2 470 0.6 17 23 29.9 272 0.5 25 808 72 19 12 123 85 and older 6 54.5 0.4 9.1 0.1 1 11

### TABLE D.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

		ANTI	HYPERTENSI	VE		ANAL	GESICS	- ANTI-INFLA	MMATOR'	Υ		
			Number of	Mean				Number of	Mean			
		Users	Benefit N	lumber of	Mean		Users	Benefit N	lumber of	Mean		
		as %	Months	Rx per	Rx \$ per		as %	Months	Rx per f	Rx \$ per		
Beneficiary	Number of	of Dual	Among	Benefit	Benefit	Number of	of Dual	Among	Benefit	Benefit	Number of	Number of
Characteristics	Users	Benes	Users	Month	Month	Users	Benes	Users	Month	Month	Beneficiaries E	Benefit Months
Male, Other Elig	ibles											
All Ages	2,867	48.3	30,631	0.7	21	997	16.8	10,856	0.5	33	5,941	58,484
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
15-20	1	25.0	11	0.8	20	1	25.0	11	0.2	2	4	39
21-44	32	22.9	362	0.5	19	47	33.6	520	0.3	29	140	1,350
45-64	36	28.6	369	0.7	21	32	25.4	353	0.4	52	126	1,126
65-74	1,236	52.6	13,305	0.7	23	449	19.1	4,890	0.5	34	2,351	23,758
75-84	1,136	49.0	12,319	0.7	21	336	14.5	3,728	0.5	30	2,317	23,010
85 and older	426	42.5	4,265	0.7	19	132	13.2	1,354	0.5	35	1,003	9,201
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Table D.7D includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = Deneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

#### TABLE D.8 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>

#### DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
All	\$375	7.2	2,265	21,475
Age				
0-64	708	9.3	104	1,087
65-74	532	9.0	234	2,376
75-84	403	7.7	745	7,200
85 and older	288	6.2	1,182	10,812
Unknown	0	0.0	0	0
Gender				
Female	361	7.0	1,609	15,714
Male	411	7.8	656	5,761
Unknown	0	0.0	0	0
Race				
White	381	7.3	1,599	15,494
African American	520	7.8	2	17
Other/unknown	358	6.9	664	5,964
Basis of Eligibility	:			
Aged	357	7.1	2,147	20,261
Disabled	675	9.2	118	1,214
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.
a. Table D.8 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible ebecause of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

#### TABLE D.9 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

#### BY BRAND STATUS AND THERAPEUTIC CATEGORYA, b, c, d, e **DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005**

Number of Rx per Benefit \$ per Benefit Month Among Month Among Users Users \$ per Rx Users

Therapeutic Category	F Total	atented Brand- Name	Off- Patent Brand- Name G	Generic		Patented Brand- Name	Off- Patent Brand- Name G	Generic		Patented Brand- Name	Off- Patent Brand- Name (	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of Dual All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.5	0.1	0.1	0.3	\$17	\$8	\$4	\$5	\$37	\$74	\$67	\$17	7,528	\$275,573	1,653	73.0	16,493
Biologicals	0.1	0.0	0.0	0.1	4	1	0	3	43	178	0	33	93	4,044	85	3.8	949
Antineoplastic Agents	0.8	0.1	0.0	0.6	132	90	1	40	168	658	223	63	603	101,017	84	3.7	768
Endocrine/Metabolic Drugs	1.3	0.4	0.2	0.7	47	33	6	9	38	84	37	12	12,471	468,546	1,011	44.6	9,883
Cardiovascular Agents	2.1	0.5	0.0	1.6	55	34	1	20	26	73	19	12	33,083	861,355	1,629	71.9	15,736
Respiratory Agents	0.7	0.5	0.0	0.2	49	43	2	4	67	93	59	17	5,900	395,278	801	35.4	8,044
Gastrointestinal Agents	1.0	0.5	0.0	0.6	68	57	1	10	65	122	28	18	11,629	754,178	1,129	49.8	11,078
Genitourinary Agents	0.7	0.5	0.0	0.2	45	40	0	4	64	81	75	22	3,777	240,829	530	23.4	5,378
CNS Drugs	1.8	0.9	0.0	0.8	131	115	0	16	75	124	31	19	30,250	2,262,249	1,771	78.2	17,230
Stimulants/Anti-obesity/Anorexia	0.8	0.1	0.0	0.6	36	26	0	10	47	176	19	16	310	14,487	42	1.9	405
Miscellaneous Psychological/ Neurological Agents	1.1	1.1	0.0	0.0	146	145	0	1	132	133	0	79	5,011	663,384	457	20.2	4,559
Analgesics and Anesthetics	1.1	0.2	0.1	0.8	59	19	9	31	54	97	124	37	12,185	655,830	1,138	50.2	11,096
Neuromuscular Agents	1.2	0.3	0.1	0.8	69	35	3	31	57	117	53	37	10,287	591,336	849	37.5	8,536
Nutritional Products	0.7	0.0	0.0	0.7	11	0	0	10	14	11	28	14	3,788	54,508	529	23.4	5,155
Hematological Agents	1.5	0.3	0.1	1.1	61	49	2	10	40	172	22	9	9,284	372,278	634	28.0	6,150
Topical Products	0.6	0.2	0.0	0.4	24	15	1	8	42	78	86	21	7,198	302,353	1,246	55.0	12,846
Miscellaneous Products	0.3	0.2	0.0	0.1	17	10	0	7	52	47	27	60	449	23,222	138	6.1	1,380
Unknown Therapeutic Category	0.3	0.0	0.0	0.0	5	0	0	0	14	0	0	0	359	5,158	101	4.5	1,044
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	154,205	8,045,625	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

In Vermont, 0.3 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.9 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

#### TABLE D.10 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,

#### BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

			Users				Among Users
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Monthsp	Number of Rx er Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$1,402,799	1,087	48.0	10,810	0.9	\$150	\$130
ANTIDEPRESSANTS	768,757	1,643	72.5	16,472	0.9	50	47
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	665,387	556	24.5	5,602	0.9	132	119
ULCER DRUGS	638,673	1,015	44.8	10,108	0.8	77	63
ANALGESICS - Narcotic	427,344	1,067	47.1	10,566	0.8	50	40
ANTICONVULSANT	368,440	579	25.6	5,932	1.1	55	62
ANTIHYPERLIPIDEMIC	358,649	406	17.9	4,185	0.9	94	86
ANTIASTHMATIC	321,027	810	35.8	8,062	0.5	77	40
ANTIDIABETIC	277,589	695	30.7	6,750	0.9	44	41
ANALGESICS - ANTI-INFLAMMATORY	200,592	382	16.9	4,128	0.7	74	49
Total	5,429,257	8,240		82,615	n.a.	n.a.	n.a.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$= Medicaid reimbursement.

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.
a. Table D.10 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

All Top	o 10 Drug Groups		DONE ELICI	ANTIPS)	CHOTICS	70111, 200			ANTIDEP	RESSANTS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	
All	70,140	\$5,429,257	1,087	48.0	10,810	0.9	\$130	1,643	72.5	16,472	0.9	\$47
Female												
All Females	49,687	3,855,548	751	46.7	7,658	0.8	130	1,186	73.7	12,109	0.9	46
Female, Disabled												
All Ages	2,931	335,801	38	66.7	434	1.1	237	49	86.0	536	1.0	61
64 or younger	2,594	312,274	34	70.8	386	1.1	247	44	91.7	476	1.0	62
65-74	240	14,810	1	16.7	12	1.1	159	4	66.7	48	0.8	59
75-84	97	8,717	3	150.0	36	0.6	151	1	50.0	12	1.4	55
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	46,756	3,519,747	713	45.9	7,224	0.8	123	1,137	73.3	11,573	0.9	45
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	6,104	503,904	86	72.3	936	1.1	179	99	83.2	1,049	1.0	49
75-84	17,079	1,338,467	224	46.5	2,361	0.8	135	417	86.5	4,306	0.9	44
85 and older	23,573	1,677,376	403	42.4	3,927	0.8	103	621	65.3	6,218	0.9	46
Male												
All Males	20,453	1,573,709	336	51.2	3,152	0.9	130	457	69.7	4,363	0.9	48
Male, Disabled												
All Ages	2,474	225,203	32	52.5	325	0.9	173	46	75.4	463	1.0	57
64 or younger	2,347	210,936	32	57.1	325	0.9	173	44	78.6	439	1.0	58
65-74	64	10,194	0	0.0	0	0.0	0	1	25.0	12	1.0	72
75-84	63	4,073	0	0.0	0	0.0	0	1	100.0	12	0.9	15
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Eligibles												
All Ages	17,979	1,348,506	304	51.1	2,827	0.9	125	411	69.1	3,900	0.9	47
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	4,569	348,889	49	46.7	539	1.1	192	88	83.8	954	0.9	50
75-84	8,399	628,985	145	55.8	1,396	0.9	110	182	70.0	1,780	0.9	45
85 and older	5,011	370,632	110	47.8	892	0.8	108	141	61.3	1,166	1.0	49
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table D.10A includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinibisherient and action of the control of the cont

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE D.10B

#### MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL				C AND	ULCER DRUGS							ANALGESICS - Narcotic			
Beneficiary Characteristics	Number of Users	Year Nursing Facility	U	Mean Number of Rx		Number of Users	Users as % of All- Year Nursing Facility Residents		Mean Number of Rx		Number of Users	Year Nursing Facility	Number of Benefit Months Among	Mean Number of Rx	
All	556	24.5	5,602	0.9	\$119	1,015	44.8	10,108	0.8	\$63	1,067	47.1	10,566	0.8	\$40
Female															
All Females	406	25.2	4,197	0.9	120	722	44.9	7,299	0.8	63	785	48.8	7,904	0.8	39
Female, Disable	ed														
All Ages	8	14.0	93	0.5	345	30	52.6	320	1.0	109	34	59.6	352	1.1	105
64 or younger	7	14.6	81	0.6	393	27	56.3	284	1.0	113	28	58.3	300	1.2	122
65-74	1	16.7	12	0.2	21	3	50.0	36	1.1	78	5	83.3	40	0.5	
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	50.0	12	0.3	2
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
Female, Other E	Eligibles														
All Ages	398	25.6	4,104	0.9	115	692	44.6	6,979	0.8	61	751	48.4	7,552	0.8	36
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
65-74	29	24.4	325	1.1	127	58	48.7	613	0.9	71	59	49.6	645	1.0	27
75-84	142	29.5	1,523	0.9	115	222	46.1	2,293	0.8	66	234	48.5	2,356	0.9	43
85 and older	227	23.9	2,256	0.9	112	412	43.3	4,073	0.8	57	458	48.2	4,551	0.7	34
Male															
All Males	150	22.9	1,405	0.9	116	293	44.7	2,809	0.8	64	282	43.0	2,662	0.9	45
Male, Disabled															
All Ages	5	8.2	55	0.6	179	38	62.3	417	0.8	65	40	65.6	412	1.0	89
64 or younger	5	8.9	55	0.6	179	34	60.7	369	0.8	63	35	62.5	363	1.0	84
65-74	0	0.0	0	0.0	0	2	50.0	24	0.6	82	3	75.0	25	0.9	239
75-84	0	0.0	0	0.0	0	2	200.0	24	0.9	86	2	200.0	24	0.1	1
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
Male, Other Elig	jibles														
All Ages	145	24.4	1,350	0.9	114	255	42.9	2,392	0.8	63	242	40.7	2,250	0.8	37
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C
65-74	17	16.2	191	0.9	101	44	41.9	444	0.8	72	52	49.5	517	1.0	41
75-84	54	20.8	526	0.9	122	118	45.4	1,171	0.8	69	110	42.3	1,091	0.8	35
85 and older	74	32.2	633	0.9	111	93	40.4	777	0.7	51	80	34.8	642	0.7	37
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	C

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.10B includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis.

In hulasing racinities for part of their entollime that their hours were excluded from the analysis.

A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

## TABLE D.10C MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND $AGE^{a, b, c, d}$

DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

	ANTICONVULSANT ANTIHYPERLIPIDEMIC							ANTIAS	THMATIC						
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx		Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among			Number of Users	Users as % of All-Year Nursing Facility Residents	Benefit Months Among	Mean Number of Rx	
All	579	25.6	5,932	1.1	\$62	406	17.9	4,185	0.9	\$86	810	35.8	8,062	0.5	\$40
Female															
All Females	364	22.6	3,776	1.1	58	272	16.9	2,885	0.9	86	519	32.3	5,317	0.5	37
Female, Disable	ed														
All Ages	34	59.6	383	1.4	128	16	28.1	168	0.8	74	34	59.6	363	0.7	61
64 or younger	30	62.5	335	1.4	136	13	27.1	132	0.8	79	31	64.6	327	0.7	60
65-74	4	66.7	48	1.1	68	2	33.3	24	0.7	42	2	33.3	24	0.7	73
75-84	0	0.0	0	0.0	0	1	50.0	12	1.1	82	1	50.0	12	1.1	81
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other E	ligibles														
All Ages	330	21.3	3,393	1.1	50	256	16.5	2,717	0.9	86	485	31.3	4,954	0.5	36
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	68	57.1	750	1.2	62	43	36.1	475	1.0	94	48	40.3	523	0.5	39
75-84	135	28.0	1,367	1.0	55	116	24.1	1,239	0.9	85	186	38.6	1,962	0.5	44
85 and older	127	13.4	1,276	1.0	39	97	10.2	1,003	0.9	85	251	26.4	2,469	0.4	28
Male															
All Males	215	32.8	2,156	1.2	69	134	20.4	1,300	0.9	86	291	44.4	2,745	0.6	45
Male, Disabled															
All Ages	39	63.9	399	1.3	84	4	6.6	45	0.8	92	44	72.1	451	0.4	35
64 or younger	37	66.1	386	1.3	85	4	7.1	45	0.8	92	40	71.4	403	0.5	35
65-74	1	25.0	1	1.0	272	0	0.0	0	0.0	0	1	25.0	12	0.2	2
75-84	1	100.0	12	1.0	19	0	0.0	0	0.0	0	3	300.0	36	0.4	44
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Male, Other Elig	ibles														
All Ages	176	29.6	1,757	1.2	66	130	21.8	1,255	0.9	86	247	41.5	2,294	0.6	47
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	56	53.3	602	1.3	69	44	41.9	453	1.0	94	41	39.0	403	0.6	36
75-84	74	28.5	750	1.1	72	62	23.8	571	0.9	83	129	49.6	1,250	0.7	51
85 and older	46	20.0	405	1.1	49	24	10.4	231	0.9	76	77	33.5	641	0.5	44
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.10C includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. wedicald relinibisherient and action of the control of the cont

# TABLE D.10D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

ANTIDIABETIC ANALGESICS - ANTI-INFLAMMATORY

Beneficiary	Number of	Users as % of All-Year Nursing Facility	Benefit Months	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	All-Year Nursing Facility	Benefit Months Among All- Year Nursing Facility
Characteristics	Users	Residents		of Rx	Rx \$		Residents		of Rx	Rx \$	Residents	Residents
All	695	30.7	6,750	0.9	\$41	382	16.9	4,128	0.7	\$49	2,265	21,475
Female												
All Females	482	30.0	4,905	0.9	43	294	18.3	3,227	0.7	49	1,609	15,714
Female, Disable	ed											
All Ages	17	29.8	192	1.0	54	12	21.1	136	0.5	18	57	615
64 or younger	11	22.9	120	1.1	77	11	22.9	124	0.5	18	48	528
65-74	4	66.7	48	0.7	9	1	16.7	12	0.7	21	6	62
75-84	2	100.0	24	1.2	27	0	0.0	0	0.0	0	2	24
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
Female, Other E	ligibles											
All Ages	465	30.0	4,713	0.9	43	282	18.2	3,091	0.7	50	1,552	15,099
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	63	52.9	674	1.1	64	22	18.5	257	0.7	110	119	1,237
75-84	192	39.8	1,973	0.9	46	102	21.2	1,122	0.6	40	482	4,857
85 and older	210	22.1	2,066	0.9	32	158	16.6	1,712	0.7	49	951	9,005
Male												
All Males	213	32.5	1,845	1.0	36	88	13.4	901	0.7	47	656	5,761
Male, Disabled												
All Ages	13	21.3	132	1.3	83	9	14.8	87	0.8	58	61	599
64 or younger	13	23.2	132	1.3	83	7	12.5	63	0.9	62	56	559
65-74	0	0.0	0	0.0	0	1	25.0	12	1.0	91	4	28
75-84	0	0.0	0	0.0	0	1	100.0	12	0.1	1	1	12
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
Male, Other Elig	jibles											
All Ages	200	33.6	1,713	0.9	32	79	13.3	814	0.7	46	595	5,162
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	51	48.6	478	1.0	38	16	15.2	185	0.6	50	105	1,049
75-84	93	35.8	819	0.9	34	37	14.2	408	0.7	46	260	2,307
85 and older	56	24.3	416	0.9	22	26	11.3	221	0.6	43	230	1,806
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

a. Table D.10D includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 1,055 beneficiaries who were in nursing facilities for part of their enrollment and their 10,388 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentld=09e0f1de-80a9-4a87-8bc9-ad77847b615 (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

#### TABLE D.11 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup> VERMONT, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	\$ per	Total Part D Excluded Rx \$	Property Performs Property Performs Performs Property Performs Per		Total Number of Beneficiaries
All	15,864	50.5	5.3	165,995	\$79	\$2,478,137	\$15	2.4	31,392
Age									
5 and younger	1	100.0	33.0	33	275	275	8	1.7	1
6-14	1	100.0	15.0	15	520	520	35	3.5	1
15-20	13	26.0	1.5	75	26	1,299	17	1.2	50
21-44	2,174	49.3	4.7	20,566	118	518,867	25	3.2	4,408
45-64	3,919	57.0	6.8	46,658	107	734,488	16	2.4	6,874
65-74	3,275	44.6	4.4	31,937	61	444,954	14	2.1	7,341
75-84	3,848	48.8	4.8	37,737	59	465,208	12	2.1	7,887
85 and older	2,633	54.5	6.0	28,974	65	312,526	11	2.7	4,830
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility	c								
Aged	8,896	47.9	4.7	88,100	59	1,094,477	12	2.2	18,577
Disabled	6,661	54.6	6.2	75,536	108	1,311,975	17	2.6	12,202
Adults	301	49.8	3.8	2,314	118	71,174	31	3.8	604
Children	6	75.0	5.6	45	64	511	11	2.4	8
Unknown	0	0.0	0.0	0	0	0	0	0.0	1
Gender									
Female	10,632	55.1	5.9	114,362	86	1,656,848	14	2.6	19,291
Male	5,232	43.2	4.3	51,633	68	821,289	16	2.1	12,101
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Race									
White	11,396	54.0	6.1	128,047	87	1,847,653	14	2.5	21,119
African American	44	47.3	4.0	373	82	7,666	21	2.2	93
Other/unknown	4,424	43.5	3.7	37,575	61	622,818	17	2.3	10,180
Use of Nursing Fa	cilities <sup>d</sup>								
Entire year	1,568	69.2	7.9	17,873	84	189,967	11	2.4	2,265
Part year	843	79.9	11.3	11,939	110	116,163	10	2.9	1,055
None	13,453	47.9	4.9	136,183	77	2,172,007	16	2.4	28,072
Maintenance Assis	stance Status								
Cash	3,830	54.2	6.5	46,217	96	677,579	15	2.6	7,063
Medically needy	3,514	53.5	5.9	38,720	92	604,650	16	2.6	6,571
Poverty related	6	42.9	1.3	18	20	277	15	2.7	14
Other/unknown	8,514	48.0	4.6	81,040	67	1,195,631	15	2.2	17,744

a. Table D.11 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

# TABLE D.12 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup> VERMONT, 2005

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazapine \$ per Benefit Month	Number of Benefit Months
All	0.5	\$8	\$15	\$0	\$3	329,992
Age						
5 and younger	2.8	23	8	0	0	12
6-14	1.3	43	35	0	1	12
15-20	0.1	2	17	0	1	551
21-44	0.4	11	25	0	4	47,340
45-64	0.6	10	16	0	4	73,850
65-74	0.4	6	14	0	2	77,203
75-84	0.5	6	12	0	2	82,725
85 and older	0.6	6	11	0	2	48,299
Unknown	0.0	0	0	0	0	0
Basis of Eligibility	y <sup>c</sup>					
Aged	0.5	6	12	0	2	191,607
Disabled	0.6	10	17	0	4	132,476
Adults	0.4	12	31	0	3	5,833
Children	0.6	7	11	0	6	73
Unknown	0.0	0	0	0	0	3
Gender						
Female	0.6	8	14	0	3	205,259
Male	0.4	7	16	0	3	124,733
Unknown	0.0	0	0	0	0	0
Race						
White	0.6	8	14	0	3	226,649
African American	0.4	8	21	0	2	949
Other/unknown	0.4	6	17	0	2	102,394
Use of Nursing Fa	acilities <sup>d</sup>					
Entire year	0.8	9	11	0	2	21,475
Part year	1.1	11	10	0	3	10,388
None	0.5	7	16	0	3	298,129
Maintenance Ass	istance Status					
Cash	0.6	8	15	0	3	80,296
Medically needy	0.6	9	16	0	3	69,597
Poverty related	0.2	3	15	0	1	106
Other/unknown	0.5	7	15	0	2	179,993

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.12 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

or blindness. The children's group includes children receiving foster care and adoptive services.

or blindness. The children's group includes children receiving foster care and adoptive services.
d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE D.13 USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS $^{a,b,c}$  VERMONT, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
All	23,087	\$107	\$2,478,137	100.0	165,995	\$15	100.0
Anorexia or weight loss/gain	21	438	9,190	0.4	98	94	0.1
Fertility drugs	0	0	0	0.0	0	0	0.0
Drugs for cosmetic purposes	10	21	212	0.0	16	13	0.0
Cough and cold medications	2,173	64	140,059	5.7	4,792	29	2.9
Vitamins and minerals	3,665	114	419,626	16.9	23,854	18	14.4
Non-prescription drugs	8,286	92	765,559	30.9	68,198	11	41.1
Barbiturates	230	59	13,621	0.5	2,540	5	1.5
Benzodiazepines	8,225	106	868,340	35.0	64,308	14	38.7
Other Part D Excl Rx Drugs	477	548	261,530	10.6	2,189	119	1.3

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.13 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table D11.
b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

#### SUPPLEMENTAL TABLE 1 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES<sup>a, b</sup> VERMONT, 2005

Total Number of Dual Eligible Beneficiaries: 31,392
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries: \$102,478,031
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary: \$3,264

Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries	Pharmacy Reimbursement	Percent of Total Pharmacy Reimbursement
\$0	2,388	7.6	\$0	0.0
•			•	
1-500	4,526	14.4	958,355	0.9
501-1,000	3,127	10.0	2,333,408	2.3
1,001-1,500	2,776	8.8	3,450,992	3.4
1,501-2,000	2,497	8.0	4,367,517	4.3
2,001-2,500	2,196	7.0	4,937,288	4.8
2,501-3,000	1,925	6.1	5,281,089	5.2
3,001-3,500	1,657	5.3	5,371,226	5.2
3,501-4,000	1,489	4.7	5,568,727	5.4
4,001-4,500	1,258	4.0	5,338,948	5.2
4,501-5,000	1,045	3.3	4,958,058	4.8
5,001-5,500	898	2.9	4,709,020	4.6
5,501-6,000	784	2.5	4,501,999	4.4
6,001-6,500	644	2.1	4,022,607	3.9
6,501-7,000	512	1.6	3,455,992	3.4
7,001-7,500	483	1.5	3,496,122	3.4
7,501-8,000	388	1.2	3,006,939	2.9
8,001-8,500	329	1.0	2,707,881	2.6
8,501-9,000	302	1.0	2,641,052	2.6
9,001-9,500	237	0.8	2,190,734	2.1
9,501-10,000	202	0.6	1,968,963	1.9
10,001+	1,729	5.5	27,211,114	26.6

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

#### SUPPLEMENTAL TABLE 1A MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE $65^{\rm a},\,{\rm b},\,{\rm c}$ VERMONT, 2005

Total Number of Disabled Dual Eligible Beneficiaries, Age < 65: 10,804

Total Pharmacy Reimbursement for Disabled Dual Eligible Beneficiaries, Age < 65: \$45,562,767

Mean Pharmacy Reimbursement per Disabled Dual Eligible Beneficiary, Age < 65: \$4,217

		Percent of Disabled Dual Beneficiaries,		Percent of Total Pharmacy
Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries	Age < 65	Pharmacy Reimbursement	Reimbursement
\$0	932	8.6	0	0.0
1-500	1,723	15.9	335,904	0.7
501-1,000	880	8.1	644,059	1.4
1,001-1,500	741	6.9	923,187	2.0
1,501-2,000	609	5.6	1,059,452	2.3
2,001-2,500	600	5.6	1,348,024	3.0
2,501-3,000	527	4.9	1,446,146	3.2
3,001-3,500	478	4.4	1,545,498	3.4
3,501-4,000	443	4.1	1,658,983	3.6
4,001-4,500	394	3.6	1,676,422	3.7
4,501-5,000	326	3.0	1,548,996	3.4
5,001-5,500	293	2.7	1,538,643	3.4
5,501-6,000	277	2.6	1,591,992	3.5
6,001-6,500	227	2.1	1,418,683	3.1
6,501-7,000	212	2.0	1,430,605	3.1
7,001-7,500	203	1.9	1,470,368	3.2
7,501-8,000	168	1.6	1,301,649	2.9
8,001-8,500	159	1.5	1,309,136	2.9
8,501-9,000	149	1.4	1,304,376	2.9
9,001-9,500	133	1.2	1,228,547	2.7
9,501-10,000	107	1.0	1,043,614	2.3
10,001+	1,223	11.3	19,738,483	43.3

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.
c. This table is limited to dual eligible beneficiaries who were under age 65 and also indicated as disabled in the MAX files. Therefore, dual eligible beneficiaries under age 65 in "adults" or "children" basis-of-eligibility categories in Table D.2 are excluded because they were not classified as disabled in the MAX files. Disabled dual eligible beneficiaries age 65 and older are included in Supplemental Tables 1B through 1E, depending on their age.

## SUPPLEMENTAL TABLE 1B MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER<sup>A, b</sup> VERMONT, 2005

Total Number of Dual Eligible Beneficiaries, Age 65+: 20,058

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65+: \$55,130,720

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65+: \$2,748

	F	Percent of Dual Beneficiaries, Age 65		Percent of Total Pharmacy
Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries	+	Pharmacy Reimbursement	Reimbursement
\$0	1,398	7.0	0	0.0
1-500	2,699	13.5	603,974	1.1
501-1,000	2,196	10.9	1,652,505	3.0
1,001-1,500	1,993	9.9	2,476,103	4.5
1,501-2,000	1,854	9.2	3,248,709	5.9
2,001-2,500	1,562	7.8	3,513,295	6.4
2,501-3,000	1,375	6.9	3,772,198	6.8
3,001-3,500	1,159	5.8	3,760,821	6.8
3,501-4,000	1,021	5.1	3,816,504	6.9
4,001-4,500	856	4.3	3,628,713	6.6
4,501-5,000	704	3.5	3,337,700	6.1
5,001-5,500	592	3.0	3,101,667	5.6
5,501-6,000	497	2.5	2,852,147	5.2
6,001-6,500	405	2.0	2,528,950	4.6
6,501-7,000	292	1.5	1,972,436	3.6
7,001-7,500	269	1.3	1,945,299	3.5
7,501-8,000	215	1.1	1,666,594	3.0
8,001-8,500	165	0.8	1,357,393	2.5
8,501-9,000	149	0.7	1,302,103	2.4
9,001-9,500	98	0.5	906,224	1.6
9,501-10,000	90	0.4	876,435	1.6
10,001+	469	2.3	6,810,950	12.4

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2005.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

#### SUPPLEMENTAL TABLE 1C MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74<sup>a, b</sup> VERMONT, 2005

Total Number of Dual Eligible Beneficiaries, Age 65-74: 7,341

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65-74: \$21,578,878

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65-74: \$2,939

		Percent of Dual Beneficiaries, Age		Percent of Total Pharmacy
Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries	65-74	Pharmacy Reimbursement	Reimbursement
\$0	625	8.5	0	0.0
1-500	978	13.3	205,594	1.0
501-1,000	744	10.1	560,358	2.6
1,001-1,500	680	9.3	851,837	3.9
1,501-2,000	645	8.8	1,132,087	5.2
2,001-2,500	534	7.3	1,200,859	5.6
2,501-3,000	478	6.5	1,309,004	6.1
3,001-3,500	406	5.5	1,317,139	6.1
3,501-4,000	373	5.1	1,394,014	6.5
4,001-4,500	289	3.9	1,225,666	5.7
4,501-5,000	242	3.3	1,147,354	5.3
5,001-5,500	195	2.7	1,020,912	4.7
5,501-6,000	195	2.7	1,121,053	5.2
6,001-6,500	151	2.1	942,603	4.4
6,501-7,000	132	1.8	893,500	4.1
7,001-7,500	106	1.4	767,885	3.6
7,501-8,000	90	1.2	699,301	3.2
8,001-8,500	64	0.9	526,715	2.4
8,501-9,000	70	1.0	611,782	2.8
9,001-9,500	50	0.7	462,371	2.1
9,501-10,000	45	0.6	438,845	2.0
10,001+	249	3.4	3,749,999	17.4

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.
a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

## SUPPLEMENTAL TABLE 1D MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO $84^{\rm A,\ b}$ VERMONT, 2005

Total Number of Dual Eligible Beneficiaries, Age 75-84: 7,887

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 75-84: \$22,116,138

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 75-84: \$2,804

Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries Percent of Dual Bene	ficiarios Ago 75.94	Pharmacy Poimburgoment	Percent of Total Pharmacy Reimbursement
\$0		6.7	0	0.0
•	529			
1-500	951	12.1	217,606	1.0
501-1,000	824	10.4	622,998	2.8
1,001-1,500	792	10.0	977,377	4.4
1,501-2,000	716	9.1	1,254,066	5.7
2,001-2,500	625	7.9	1,405,573	6.4
2,501-3,000	561	7.1	1,542,187	7.0
3,001-3,500	483	6.1	1,570,039	7.1
3,501-4,000	413	5.2	1,542,982	7.0
4,001-4,500	379	4.8	1,605,387	7.3
4,501-5,000	301	3.8	1,426,644	6.5
5,001-5,500	262	3.3	1,373,263	6.2
5,501-6,000	208	2.6	1,190,814	5.4
6,001-6,500	182	2.3	1,135,851	5.1
6,501-7,000	105	1.3	708,118	3.2
7,001-7,500	114	1.4	823,872	3.7
7,501-8,000	84	1.1	651,217	2.9
8,001-8,500	72	0.9	591,216	2.7
8,501-9,000	45	0.6	392,725	1.8
9,001-9,500	32	0.4	295,757	1.3
9,501-10,000	32	0.4	310,741	1.4
10,001+	177	2.2	2,477,705	11.2

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2005.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

#### SUPPLEMENTAL TABLE 1E MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER<sup>a, b</sup> VERMONT, 2005

Total Number of Dual Eligible Beneficiaries, Age 85+: 4,830
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 85+: \$11,435,704
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 85+: \$2,367

	Percen	nt of Dual Beneficiaries, Age 85		Percent of Total Pharmacy	
Annual Pharmacy Reimbursement per Beneficiary	Number of Beneficiaries	+	Pharmacy Reimbursement	Reimbursement	
\$0	244	5.1	0	0.0	
1-500	770	15.9	180,774	1.6	
501-1,000	628	13.0	469,149	4.1	
1,001-1,500	521	10.8	646,889	5.7	
1,501-2,000	493	10.2	862,556	7.5	
2,001-2,500	403	8.3	906,863	7.9	
2,501-3,000	336	7.0	921,007	8.1	
3,001-3,500	270	5.6	873,643	7.6	
3,501-4,000	235	4.9	879,508	7.7	
4,001-4,500	188	3.9	797,660	7.0	
4,501-5,000	161	3.3	763,702	6.7	
5,001-5,500	135	2.8	707,492	6.2	
5,501-6,000	94	1.9	540,280	4.7	
6,001-6,500	72	1.5	450,496	3.9	
6,501-7,000	55	1.1	370,818	3.2	
7,001-7,500	49	1.0	353,542	3.1	
7,501-8,000	41	0.8	316,076	2.8	
8,001-8,500	29	0.6	239,462	2.1	
8,501-9,000	34	0.7	297,596	2.6	
9,001-9,500	16	0.3	148,096	1.3	
9,501-10,000	13	0.3	126,849	1.1	
10,001+	43	0.9	583,246	5.1	

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2005.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

#### APPENDIX TABLE A.3

#### CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

	DUAL ELIGIBLE BENEFICIARIES, VERMONT, Number of Beneficiaries						Number of Benefit Months					
Beneficiary Characteristics	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
All	31,401	18,579	12,209	604	8	1	330,019	191,613	132,497	5,833	73	3
Age												
5 and younger	1	0	1	0	0	0	12	0	12	0	0	0
6-14	1	0	1	0	0	0	12	0	12	0	0	0
15-20	50	0	42	2	6	0	551	0	474	21	56	0
21-44	4,408	0	4,124	283	1	0	47,340	0	44,566	2,769	5	0
45-64	6,877	3	6,639	234	1	0	73,859	29	71,615	2,203	12	0
65-74	7,344	6,190	1,072	81	0	1	77,212	64,239	12,172	798	0	3
75-84	7,889	7,605	281	3	0	0	82,731	79,585	3,116	30	0	0
85 and older	4,831	4,781	49	1	0	0	48,302	47,760	530	12	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Gender												
Female	19,296	12,946	6,045	299	5	1	205,274	136,000	66,236	2,989	46	3
Male	12,105	5,633	6,164	305	3	0	124,745	55,613	66,261	2,844	27	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
Race												
White	21,124	10,468	10,187	464	5	0	226,664	110,444	111,540	4,628	52	0
African American	93	12	76	5	0	0	949	123	775	51	0	0
Other/unknown	10,184	8,099	1,946	135	3	1	102,406	81,046	20,182	1,154	21	3
Use of Nursing Facilities <sup>c</sup>												
Entire year	2,265	2,147	118	0	0	0	21,475	20,261	1,214	0	0	0
Part year	1,055	891	161	3	0	0	10,388	8,695	1,662	31	0	0
None	28,081	15,541	11,930	601	8	1	298,156	162,657	129,621	5,802	73	3
Maintenance Assistance Statu	ıs											
Cash	7,063	1,402	5,606	54	1	0	80,296	15,574	64,127	583	12	0
Medically needy	6,571	3,366	3,110	92	3	0	69,597	36,003	32,689	883	22	0
Poverty related	14	0	0	13	0	1	106	0	0	103	0	3
Other/unknown	17,753	13,811	3,493	445	4	0	180,020	140,036	35,681	4,264	39	0
Dual Status <sup>d</sup>												
Full dual, all year	31.401	18,579	12,209	604	8	1	330,019	191,613	132,497	5,833	73	3
Full dual, part year	0	0	0	0	0	0	0	0	0	0	0	0
Managed Care (MC) Status												
Fee-for-service (FFS) all year	31,392	18,577	12,202	604	8	1	329,992	191,607	132,476	5,833	73	3
FFS part year, with Rx claims	0.,552	0	0	0	0	0	0	0	0	0,000	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

a. Table A.3 includes the beneficiaries represented by Cell F of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability

or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

are not consistent with basis or engionity.

C. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid pharmacy benefits during all months of Medicaid enrollment in 2005. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status. Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

#### APPENDIX TABLE A.4

### MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup> DUAL ELIGIBLE BENEFICIARIES, VERMONT, 2005

	Benefit Month	aries and ns in Cell F of ble 1	Included in Ce	ell G of Table 1	Excluded from (	Cell G of Table 1
Beneficiary Characteristics	Number of Beneficiaries	Number of	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
All	31,401	330,019	31,392	329,992	0	27
Fee-for-service (FFS) all year	31,392	329,992	31,392	329,992	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Vermont, released by CMS in 12/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.